- recruitingPHASE3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
This study is looking into a new medication called efruxifermin for people with a kind of liver disease called NASH/MASH and scarring (fibrosis). It's a large study where some people get the medication, and others get a dummy treatment, to see if it's safe and helps improve the liver condition.
United States · Argentina · Australia - recruiting
Global Research Initiative for Patients Screening on MASH
This study aims to improve how doctors find serious liver conditions like MASH in people with health problems like diabetes or obesity. It brings together healthcare providers across Europe to use new care guidelines and raise awareness about these liver diseases.
Belgium · Czechia · France - recruitingNA
Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)
This study looks into how a sugar called fructose might affect people with MASH, a liver condition. Researchers will compare fructose to another sugar, glucose, over four weeks to see if it causes more inflammation or affects liver fat in people with MASH compared to those with less severe liver issues or healthy people.
United Kingdom